BioSpace News Archive

With the escalating need for storing unstable pharmaceutical components, the dual chamber prefilled syringes garner attention as excellent sterile drug injector syringes.

Disposable face masks are witnessing higher demand for themselves in current times because of the COVID-19 pandemic. These products are used to protect the face and nose from contamination.

Congenital adrenal hyperplasia refers to a group of genetic conditions that affect the adrenal glands leading to low levels of cortisol and high levels of male hormones called androgens, causing development of male characteristics in females, and early puberty in both boys and girls.

Carrier screening is a genetic test used to determine if a healthy person is a carrier of a recessive genetic disease or a gene for certain genetic disorders.

Carbuncle is a bacterial infection that infects the hair follicles on skin. It is primarily caused by bacteria Staphylococcus aureus. Scrapes, broken skin, and moist parts of the body are the favorable conditions for carbuncle infection.

Adoption of convolutional neural network and deep learning has increased the precision and accuracy in diagnostic imaging techniques, widening the growth opportunities for market players

Oblique Therapeutics AB, a Sweden-based biotech company, in collaboration with Karolinska Institutet, Gothenburg University and several local biotechs published promising research results in the highly-acclaimed scientific journal Science Advances entitled: Rational Antibody design for Undruggable Targets using Kinetically Controlled Biomolecular probes.

Exploratory analyses are looking to define subsets of patients with baseline markers indicative of increased disease severity with the potential for greater benefit

RELIEF THERAPEUTICS Holding AG, commented on certain statements made by NeuroRx, Inc., its collaboration partner for the development of RLF-100TM pursuant to that certain binding collaboration agreement, dated September 18, 2020, in Amendment No. 1 to the Form S-4 of Big Rock Partners Acquisition Corp.'s that was filed on Friday, April 16, 2021.

Phase 2a trial in non-small cell lung cancer expected to begin enrollment in the US in the second half of 2021